LearnGlossaryMarketStocksSuperinvestorsSign in

RPRX

Royalty Pharma plc

Healthcare · $25.9B market cap

Verdict

Share price

$57.16

close of Oct 3, 2026

Fair value

$26.13

Sticker Price

Payback Price

$10.45

buy price

Overpriced

RPRX is Overpriced: at $57.16 it trades 119% above its fair value of $26.13. Its buy price (Payback Price) is $10.45, 82% below today's price. Business quality is limited: none of the 5 key numbers clears the 10% bar.

How we valued it

Free Cash Flow Growth. Reported earnings are shrinking, but free cash flow keeps growing, so we value it on cash flow.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-1.7% a year✗
Equity per share growth3.1% a year✗
Sales growth4.0% a year✗
Free cash flow growth8.7% a year✗
Return on invested capital8.4%✗

Follow RPRX

Get notified when it reaches its buy price of $10.45. Free.

Create a free account

Superinvestors

3 of the investors we track hold RPRX. Who we track

Samantha McLemore

Patient Capital Management · as of Q2 2026

$201.8M

3,598,808 shares

Pat Dorsey

Dorsey Asset Management · as of Q2 2026

$137.7M

2,456,528 shares

Torray Funds

Torray Funds · as of Q2 2026

$33.8M

602,028 shares

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was…

Medical - Pharmaceuticals

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works